A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: IBI318; Procedure: cTACE; Drug: placebo Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research | Study